Answers are grounded in this paper and cite their sources.
Abnormal genital arousal and genital sensations, including Persistent Genital Arousal Disorder (PGAD), are conditions characterized by unwanted, persistent genital arousal, orgasms, or sensory abnormalities that occur without sexual desire or stimulation, often lasting days or weeks.1,2 These abnormalities are not commonly reported by patients, and the underreporting is likely due to embarrassment or fear of having a diagnosis of sexual dysfunction or being mislabeled as “hypersexual” in the case of PGAD.1 Theories on the causes of PGAD include dysfunction or compression of the pudendal nerve, which innervates the genital and perineal regions, sacral Tarlov cysts, medication effects, or comorbid neurological disorders, such as restless leg syndrome (RLS), genital sensory hyperesthesia, sensory neuropathy, and others.1,2 Small fiber neuropathy (SFN) in general may be associated with pelvic and genital sensory alterations and erectile dysfunction.1,2 Although literature on PGAD is limited, consensus guidelines on nomenclature and treatment of PGAD were created by the International Society for the Study of Women’s Sexual Health and, subsequently, updated for all genders (Supplemental References). PGAD, or genito-pelvic dysesthesia, was defined as a sensory hyperactivity condition that involves a broad range of undesired, unrelenting dysesthesia, including genital arousal (Supplemental References). The sensory hyperactivity may be localized to the end organ, pelvis/perineum, cauda equina, spinal cord, and the brain (Supplemental References). Additionally, one study comparing 26 PGAD patients with matched healthy controls found significantly higher rates of spontaneous orgasm, excessive lubrication, and RLS among PGAD patients.1 They also experienced greater sexual dysfunction, such as loss of desire and sexual aversion, and psychiatric comorbidities, such as depression, anxiety, and lifetime panic disorder.1 The average diagnostic delay of 5 years highlights that PGAD is under-recognized, undiagnosed, and carries significant psychosocial burden.1 While Tarlov cysts were more common in the PGAD patients, the difference was not statistically significant in that study.1 However, since Tarlov cysts can cause pain and bladder dysfunction, they remain a notable finding.1 The strong association with RLS suggests overlapping SFN, dopaminergic system hyperexcitability, and other possible neurologic correlates. Another retrospective study of 10 female PGAD patients (mean age 53.4 years) revealed that 8 experienced daily sexual arousals, with masturbation offering relief in only 20% of cases.2 Conventional psychiatric and gynecologic treatments offered minimal or temporary relief, while neurological treatment—like Tarlov cyst removal—showed improved in 80% of cases.2 In this study, possible etiologies included sacral sensory lesions, abrupt withdrawal from medication (duloxetine), and autonomic neuropathies.2 Since women commonly experience autonomic disorders, SFN, autoimmunity, and antidepressants use, association with abnormal genital arousal and sensations presents an important area of research and needs to be further examined. We report a case series of 10 patients (6 females, 4 males, age range 21-62 years) with autonomic disorders and comorbidities who experienced genital symptoms associated with autonomic dysfunction (Table S1). Six patients had postural orthostatic tachycardia (POTS) and comorbidities, 4 had comorbid hypermobile Ehlers-Danlos syndrome (h-EDS) or hypermobility spectrum disorder (HSD), 4 had SFN, and 5 had autoimmune or inflammatory disorder. Importantly, 8 of 10 patients had positive autoimmune or inflammatory markers, the most common being positive anti-nuclear antibodies (Table S1). All patients reported genital sensory disturbances, ranging from loss of sensation to hyperarousal to erectile dysfunction. Therapeutic treatments varied according to comorbidities and their various underlying mechanisms and were effective in reducing genital and sexual symptoms in 6 out of 10 patients. Beta-blockers, such as atenolol and metoprolol, that are the first-line treatment of POTS, alleviated hyperarousal symptoms in patients with POTS. Immunomodulatory treatments, such as intravenous immunoglobulin (IVIG), plasmapheresis, prednisone, and rituximab, were reported to improve genital sensory symptoms, particularly among patients who had positive autoimmune markers, anti-SSA or HLA-B27. Pyridostigmine, an acetylcholinesterase inhibitor that is used for treatment of orthostatic intolerance, was beneficial for genital sensory loss in a patient with autonomic neuropathy. Sildenafil, a phosphodiesterase inhibitor, improved symptoms of erectile dysfunction in 3 male patients, with one patient reporting a reduction in the need to use sildenafil following treatment with IVIG for Sjogren’s disease (SjD), suggesting that in patients with autonomic and autoimmune disorders, erectile dysfunction may, in some cases, respond to treatment of the underlying autoimmune disorder. Collectively, these findings suggest that treatment of autonomic dysfunctions and targeted immunotherapy may potentially alleviate genital sensory symptoms in patients with autonomic and autoimmune conditions that are the likely drivers of abnormal genital arousal and sensations. POTS is one of the most common autonomic disorders characterized by abnormal heart rate elevation of greater than 30 bpm from supine to standing position, associated with dizziness/lightheadedness and palpitations.3 Other non-orthostatic symptoms are commonly present, such as fatigue, headache, cognitive impairment, and exercise intolerance. The disorder primarily affects women of reproductive age and can be triggered by menarche, pregnancy, surgery, growth spurts, and infection.3 POTS is diagnosed via a 10-min standing test or tilt table test, with at least 50% of patients demonstrating comorbid SFN, which manifests with decreased pain and/or temperature sensation, and at least 20% of patients having comorbid autoimmune disorder.3 Given that the autonomic nervous system is intricately involved in sexual function, abnormal genital arousal, and sensations are likely prevalent in patients with autonomic disorders, but are not reported or prioritized due to other more disabling and life-altering symptoms, such as chronic dizziness, orthostatic intolerance, fatigue, tachycardia, exercise intolerance, and many others. Further, women and men with POTS experience significant sexual dysfunction, scoring lower on sexual function indices (FSFI in females, IIEF in males) than age- and sex-matched healthy controls.3 Sexual dysfunction also occurs in women with systemic autoimmune rheumatic disorders, and the etiology is likely multifactorial reflecting the interplay between immune dysregulation, medication side effects, and psychological distress.4 A systematic review of 68 studies and a meta-analysis of 65 studies including 5457 women (mean age 43.7) found sexual dysfunction in over half of the participants.4 Sexual dysfunction rates were particularly high in SjD and systemic sclerosis, partly attributed to vaginal dryness, skin tightening, muscular weakness, and possible dysautonomia.4 Importantly, half of patients in our cohort had comorbid autoimmune and inflammatory disorders, including 2 patients with SjD, 2 with undifferentiated connective tissue disease, and 1 with Crohn’s disease, suggesting that autoimmunity and inflammation, in addition to autonomic dysfunction, may play a significant role in genital arousal and sensory disorders. In summary, our case series of 10 patients with autonomic disorders and comorbidities describe abnormal genital arousal and sensory symptoms that were improved by targeted therapies for autonomic dysfunction and autoimmunity. While only a subset of patients experienced PGAD, the majority reported a broader range of altered genital and pelvic sensations as well as sexual dysfunction. Findings of this case series suggest that abnormal genital sensory symptoms, erectile dysfunction, decreased libido, or genital hyperarousal, could stem from autonomic dysfunction, autoimmunity, and SFN, but further research is needed to elucidate the underlying pathophysiologic mechanisms. From clinical standpoint, recognizing and treating abnormal genital arousal and sensory symptoms as features of autonomic disorders, SFN and autoimmune conditions can expand the diagnostic and therapeutic scope and improve care for patients whose sexual dysfunction is often undiagnosed and untreated. This study received no funding support. The authors declare that they have no conflict of interest.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: